- Conditions
- Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma, Recurrent Malignant Endocrine Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Male Reproductive System Neoplasm, Recurrent Malignant Mesothelioma, Recurrent Malignant Neoplasm of Multiple Primary Sites, Recurrent Malignant Oral Neoplasm, Recurrent Malignant Pharyngeal Neoplasm, Recurrent Malignant Skin Neoplasm, Recurrent Malignant Soft Tissue Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Thyroid Gland Neoplasm, Recurrent Malignant Urinary System Neoplasm, Refractory Cutaneous Melanoma, Refractory Malignant Bone Neoplasm, Refractory Malignant Endocrine Neoplasm, Refractory Malignant Female Reproductive System Neoplasm, Refractory Malignant Male Reproductive System Neoplasm, Refractory Malignant Mesothelioma, Refractory Malignant Neoplasm of Multiple Primary Sites, Refractory Malignant Oral Neoplasm, Refractory Malignant Pharyngeal Neoplasm, Refractory Malignant Skin Neoplasm, Refractory Malignant Soft Tissue Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Malignant Thyroid Gland Neoplasm, Refractory Malignant Urinary System Neoplasm
- Interventions
- Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Cyclophosphamide, Etoposide
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Months to 40 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,057
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer, Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Melanoma (Skin Cancer), NSCLC (Non-small Cell Lung Cancer), Pancreatic (Exocrine Only), Mix of Solid Tumors (MOST)
- Interventions
- blood and tissue samples, blood and tissue samples
- Diagnostic Test · Other
- Lead sponsor
- Paradigm Health
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 2
- States / cities
- San Diego, California • Maumee, Ohio
- Conditions
- Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
- Interventions
- cisplatin, ifosfamide, paclitaxel, vinblastine
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 78
- States / cities
- Anniston, Alabama • La Jolla, California • Los Angeles, California + 57 more
- Conditions
- Head and Neck Cancer
- Interventions
- Gefitinib
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Induction Chemotherapy, Low-Risk Therapy, High-Risk Therapy, Intermediate-Risk Therapy
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 5 Years
- Enrollment
- 293 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2029
- U.S. locations
- 5
- States / cities
- Palo Alto, California • San Diego, California • Saint Paul, Minnesota + 2 more
- Conditions
- Cancer, Neuroendocrine Tumors, NET, Adrenocortical Carcinoma, ACC
- Interventions
- TKM-080301
- Drug
- Lead sponsor
- Arbutus Biopharma Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Tampa, Florida • Iowa City, Iowa + 4 more
- Conditions
- Neuroendocrine Tumors
- Interventions
- fosbretabulin tromethamine
- Drug
- Lead sponsor
- Mateon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Stanford, California • Lexington, Kentucky • The Bronx, New York + 2 more
- Conditions
- Neuroendocrine Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, High Grade Neuroendocrine Carcinoma, Any Site
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- Ochsner Health System
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Kenner, Louisiana • New Orleans, Louisiana
- Conditions
- Advanced Solid Tumor
- Interventions
- SKL27969
- Drug
- Lead sponsor
- SK Life Science, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 4
- States / cities
- Duarte, California • Grand Rapids, Michigan • Huntersville, North Carolina + 1 more
- Conditions
- Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- IOV-4001
- Biological
- Lead sponsor
- Iovance Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Miami, Florida • Orlando, Florida + 7 more
- Conditions
- Neuroendocrine Carcinoma of the Skin
- Interventions
- CMF regimen, cyclophosphamide, fluorouracil, methotrexate
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 84
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer, Sarcoma
- Interventions
- stereotactic radiosurgery
- Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 11
- States / cities
- Des Moines, Iowa • Kalamazoo, Michigan • Papillion, Nebraska + 5 more
- Conditions
- Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers
- Interventions
- DCC-2618
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 10 more
- Conditions
- Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma, Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations
- Interventions
- FT-2102, Azacitidine, Nivolumab, Gemcitabine and Cisplatin
- Drug · Biological
- Lead sponsor
- Forma Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 14
- States / cities
- Gilbert, Arizona • Aurora, Colorado • Miami, Florida + 10 more
- Conditions
- Kidney Cancer, Melanoma (Skin)
- Interventions
- denileukin diftitox
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Solid Tumors
- Interventions
- INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
- Conditions
- Malignant Head and Neck Neoplasm, Malignant Neoplasm, Metastatic Malignant Neoplasm in the Neck, Metastatic Malignant Neoplasm in the Uterine Cervix, Pancreatic Adenocarcinoma, Pancreatic Neuroendocrine Carcinoma, Recurrent Colorectal Carcinoma, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Hypopharyngeal Carcinoma AJCC v7, Stage I Major Salivary Gland Cancer AJCC v7, Stage I Nasopharyngeal Carcinoma AJCC v7, Stage I Oral Cavity Cancer AJCC v6 and v7, Stage I Oropharyngeal Carcinoma AJCC v6 and v7, Stage II Colorectal Cancer AJCC v7, Stage II Hypopharyngeal Carcinoma AJCC v6 and v7, Stage II Major Salivary Gland Cancer AJCC v7, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage II Oral Cavity Cancer AJCC v6 and v7, Stage II Oropharyngeal Carcinoma AJCC v6 and v7, Stage IIA Colorectal Cancer AJCC v7, Stage IIB Colorectal Cancer AJCC v7, Stage IIC Colorectal Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Hypopharyngeal Carcinoma AJCC v7, Stage III Laryngeal Cancer AJCC v6 and v7, Stage III Major Salivary Gland Cancer AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage III Oral Cavity Cancer AJCC v6 and v7, Stage III Oropharyngeal Carcinoma AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVA Hypopharyngeal Carcinoma AJCC v7, Stage IVA Laryngeal Cancer AJCC v7, Stage IVA Major Salivary Gland Cancer AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVA Oropharyngeal Carcinoma AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Stage IVB Hypopharyngeal Carcinoma AJCC v7, Stage IVB Laryngeal Cancer AJCC v7, Stage IVB Major Salivary Gland Cancer AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oropharyngeal Carcinoma AJCC v7, Metastatic or Locally Unresectable Solid Tumor
- Interventions
- Exercise Intervention, Health Telemonitoring, Quality-of-Life Assessment, Questionnaire Administration
- Behavioral · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Cutaneous Melanoma, Non-small Cell Lung Cancer
- Interventions
- OR502, Cemiplimab
- Drug
- Lead sponsor
- OncoResponse, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 4
- States / cities
- Austin, Texas • Irving, Texas • San Antonio, Texas + 1 more
- Conditions
- Advanced Malignancies, Metastatic Cancer
- Interventions
- INCAGN01876
- Drug
- Lead sponsor
- Incyte Biosciences International Sàrl
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 8
- States / cities
- Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 4 more
- Conditions
- Hepatoblastoma, Hepatocellular Carcinoma, Wilms Tumor, Malignant Rhabdoid Tumor, Yolk Sac Tumor, Rhabdomyosarcoma, Liposarcoma, Embryonal Sarcoma of Liver
- Interventions
- 21.15.GPC3-CAR T cells
- Genetic
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2043
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- IPH4502
- Drug
- Lead sponsor
- Innate Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Hackensack, New Jersey • New York, New York + 2 more
- Conditions
- Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Interventions
- Akt Inhibitor MK2206, Hydroxychloroquine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Acral Lentiginous Melanoma, Central Nervous System Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Leptomeningeal Neoplasm, Melanocytoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Uveal Melanoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Lumbar Puncture, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography
- Procedure · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Metastatic Cancer
- Interventions
- PVA microporous hydrospheres/doxorubicin hydrochloride
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland